This case report brings to the awareness that the opposite may occur and emphasize the need for attentive pharmacovigilance.<h4>Methods</h4>An elderly woman presented to us with relapsed/refractory (R/R) FLT3-ITD AML following azacytidine treatment, received single-agent TKI gilteritinib, selected for its greater potency and specificity. This evidence concerns the gene FLT3 and acute myeloid leukemia.